OWD
ALXN

Osborn Williams & Donohoe’s Alexion Pharmaceuticals ALXN Stock Holding History

Osborn Williams & Donohoe’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,481
Closed -$243K – 318
2019
Q3 		$243K Buy
2,481
+568
+30% +$64K 0.02% 288
2019
Q2 		$251K Sell
1,913
-145
-7% -$18.7K 0.03% 290
2019
Q1 		$283K Buy
+2,058
New +$256K 0.03% 304

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osborn Williams & Donohoe's ALXN Position: Q4 2019 in Review

Osborn Williams & Donohoe sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 2,481 shares — an estimated $243K sold.

Osborn Williams & Donohoe first reported a position in ALXN in Q1 2019 and held it in 3 quarters. The position peaked at $283K in Q1 2019. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Osborn Williams & Donohoe reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 2,481 Alexion Pharmaceuticals shares in Q4 2019, an estimated $243K.
  • Osborn Williams & Donohoe first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Osborn Williams & Donohoe's Alexion Pharmaceuticals position peaked at $283K in Q1 2019.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q4 2019, filed 2 Mar 2020.